Astellas, Pfizer discontinuing Xtandi for breast cancer

Astellas Pharma Inc. (Tokyo:4503) and Pfizer Inc. (NYSE:PFE) said they discontinued their development program for Xtandi enzalutamide to treat breast cancer. The oral androgen receptor (AR) antagonist is approved to treat metastatic castration-resistant prostate cancer (CRPC).

The partners are discontinuing the Phase III ENDEAR trial comparing Xtandi plus chemotherapy to Xtandi monotherapy in patients with advanced triple-negative breast cancer (TNBC). ENDEAR had not yet enrolled any patients...